Fms-like tyrosine kinase 3 (FLT3)

Where the papers sit

11 papers from the last 6 months study Fms-like tyrosine kinase 3 (FLT3) directly · updated from PubMed 3 Oct 2026

• FLT3-Targeted AML Therapy

  FLT3-targeted treatment in relapsed or refractory AML is moving beyond single-agent gilteritinib toward resistance-directed combinations and post-transplant maintenance. XY0206 and nintedanib address FLT3-dependent resistance, including the F691L gatekeeper mutation, while adaptor-mediated p38 MAPK signaling remains a resistance mechanism. Inobrodib combined with gilteritinib and venetoclax is aimed at leukemia stem cells in epigenetically mutated AML. Prognostic FLT3 expression and real-world maintenance outcomes keep molecular selection and remission durability as key endpoints.

  7 papers · 63.6%

• Dual Kinase Inhibition in Leukemia

  Dual-kinase inhibition is being explored as a way to broaden FLT3-directed activity in myeloid leukemia. The work pairs FLT3 targeting with SYK or TAK1 pathway inhibition and includes a SYK-HDAC inhibitor strategy. ATP-pocket mapping and structural modeling are used to explain binding and guide potency. Whether these combinations improve selectivity and durable leukemia control remains unresolved in this small preclinical literature.

  2 papers · 18.2%

• FLT3 AML Detection and Inhibition

  FLT3-mutated AML is being approached through both peritransplant molecular surveillance and improved inhibitor design. Targeted NGS and PCR-based monitoring track molecular MRD and relapse risk around allogeneic transplantation. In parallel, docking and molecular-dynamics studies seek modified FLT3 inhibitors with stronger binding stability and inhibition. The cluster does not establish a shared clinical direction, but links relapse detection with therapeutic optimization.

  2 papers · 18.2%